Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations

Isaacsson Velho, 2018, PD-1/PD-L1 pathway inhibitors in advanced prostate cancer, Expert Rev Clin Pharmacol, 11, 475, 10.1080/17512433.2018.1464388 Robinson, 2015, Integrative clinical genomics of advanced prostate cancer, Cell, 161, 1215, 10.1016/j.cell.2015.05.001 Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733 Graff, 2016, Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer, Oncotarget, 7, 52810, 10.18632/oncotarget.10547 Schweizer, 2016, Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate, Oncotarget, 7, 82504, 10.18632/oncotarget.12697 Lee, 2016, Mismatch repair deficiency and response to immune checkpoint blockade, Oncologist, 21, 1200, 10.1634/theoncologist.2016-0046 Boudadi, 2018, Ipilimumab plus nivolumab and DNA-repair defects in AR-V7–expressing metastatic prostate cancer, Oncotarget, 9, 28561, 10.18632/oncotarget.25564 Isaacsson Velho, 2018, Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer, Prostate, 78, 401, 10.1002/pros.23484 Scher, 2016, Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the Prostate Cancer Clinical Trials Working Group 3 (PCWG3), J Clin Oncol, 34, 1402, 10.1200/JCO.2015.64.2702 Guedes, 2017, MSH2 loss in primary prostate cancer, Clin Cancer Res, 23, 6863, 10.1158/1078-0432.CCR-17-0955 Hempelmann, 2018, Microsatellite instability in prostate cancer by PCR or next-generation sequencing, J Immunother Cancer, 6, 29, 10.1186/s40425-018-0341-y Pritchard, 2014, Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer, Nat Commun, 5, 4988, 10.1038/ncomms5988 Maughan, 2018, p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer, Prostate Cancer Prostatic Dis, 21, 260, 10.1038/s41391-017-0027-4 Antonarakis, 2011, Expanding treatment options for metastatic prostate cancer, N Engl J Med, 364, 2055, 10.1056/NEJMe1102758 Mercader, 2001, T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer, Proc Natl Acad Sci U S A, 98, 14565, 10.1073/pnas.251140998